Acción XLRN ACCELERON PHARMA INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate
Instrumento Inactivo

Otros idiomas Acceleron Pharma Inc.

Acciones

XLRN

US00434H1086

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
MERCK : l'expiration des brevets, moins grave pour Merck que pour se rivaux ?
Relief Therapeutics: le conseil d'administration intègre Michelle Lock
Global markets live: Airbus, BP, Merck, Pfizer, Meta...
Tout feu, tout flamme
EN DIRECT DES MARCHES : L'Oréal, Nestlé, Airbus, Soitec, Valneva, Ubisoft, HelloFresh, Derichebourg...
Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from NASDAQ Biotechnology Index
Acceleron Pharma : Completion of Acquisition or Disposition of Assets - Form 8-K
ACCELERON PHARMA INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
Merck : l'acquisition d'Acceleron est finalisée
Merck Completes Acceleron Pharma Acquisition
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc.
Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from NASDAQ Composite Index
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P Global BMI Index
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P TMI Index
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P Biotechnology Select Industry Index
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc
Merck Sharp & Dohme Corp. completed the acquisition of Acceleron Pharma Inc. from Avoro Capital Advisors LLC, Holocene Advisors, LP, Darwin Global Management Limited and others for $7.1 billion.
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's 'Inadequate' Offer
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción XLRN
  4. Noticias Acceleron Pharma Inc.
  5. Otros idiomas